HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Calcifediol (Calcidiol)

Subscribe to New Research on Calcifediol

The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.

Also Known As:

Calcidiol; Calderol; 25 Hydroxycholecalciferol; 25-Hydroxyvitamin D3; Aventis Brand of Calcifediol; Calcifediol, (3 alpha,5Z,7E)-Isomer; Calcifediol, (3 beta,5E,7E)-Isomer; Dedrogyl; Faes Brand of Calcifediol; Hidroferol; Organon Brand of Calcifediol; 25 Hydroxyvitamin D 3; 25 Hydroxyvitamin D3; Calcifediol Aventis Brand; Calcifediol Faes Brand; Calcifediol Organon Brand; 25-Hydroxycholecalciferol; 25-Hydroxyvitamin D 3; 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)-

Networked: 597 relevant articles (24 outcomes, 76 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Tuohimaa, Pentti: 6 articles (02/2010 - 01/2004)
2.	DeLuca, Hector F: 5 articles (02/2015 - 01/2006)
3.	Reichrath, Jörg: 5 articles (10/2014 - 01/2002)
4.	Moan, Johan: 5 articles (01/2008 - 03/2005)
5.	Cross, Heide S: 4 articles (02/2014 - 10/2005)
6.	Li, Wei: 4 articles (01/2014 - 02/2013)
7.	Li, Hao: 4 articles (01/2014 - 02/2013)
8.	Wang, Qi: 4 articles (01/2014 - 02/2013)
9.	Tuohimaa, P: 4 articles (01/2012 - 02/2005)
10.	Friedrich, Michael: 4 articles (11/2010 - 01/2002)

Related Diseases

1.	Osteoporosis 08/01/2009 - "In 131 postmenopausal females screened for participation in an osteoporosis trial, the 25-hydroxyvitamin D3 concentration was < 60 nmol/L. " 01/01/2010 - "The Health Council of the Netherlands advises a colecalciferol intake of 800 IU/day and an intended serum level of calcidiol of at least 50 nmol/l for people aged 50 years and older and for osteoporosis patients. " 02/01/2007 - "The association of calcidiol with the specific osteoporosis treatment, for example associating the two therapies on one specific day (once weekly) is an efficient way for increasing compliance and effectiveness of the osteoporosis therapy. " 02/01/2007 - "[Rational and results of weekly treatment with calcidiol in postmenopausal and senile osteoporosis]." 03/11/2000 - "Calcidiol serum levels were measured in 171 postmenopausal women (111 with osteoporosis and 60 without osteoporosis). "
2.	Osteomalacia 05/01/2013 - "Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia." 04/01/1986 - "We surveyed calcidiol levels (25-OH-D) in a geographically-defined population of 373 women, ages 20-80 yr to test for an association between occult osteomalacia and excess bone loss. " 01/01/1983 - "In the few patients studied, there was no relationship between osteomalacia and serum 25-hydroxycholecalciferol level. " 11/28/1981 - "Osteomalacia in presence of "normal" serum 25-hydroxycholecalciferol concentration." 12/23/1977 - "It was shown that the serum 25-hydroxycholecalciferol level and the skeletal radiograph were the most valuable in the early detection of osteomalacia. "
3.	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 07/01/1982 - "We conclude that 25-hydroxyvitamin D3 is ineffective in reversing the bone thinning in the majority of primary biliary cirrhosis patients, but it may be helpful in a few selected patients." 07/01/1982 - "Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment." 07/01/1982 - "25-Hydroxyvitamin D3 treatment of bone disease in primary biliary cirrhosis." 10/01/1981 - "Effect of 25-hydroxyvitamin D3 on vitamin D metabolites in primary biliary cirrhosis." 02/01/1979 - "We conclude that both high-dose parenteral vitamin D2 and oral 25-hydroxyvitamin D3 may be effective in healing osteomalacia associated with primary biliary cirrhosis. "
4.	Vitamin D Deficiency 08/15/2010 - "To study the basis for this weakness, severe vitamin D deficiency was produced in rats as revealed by a low level or absence of 25-hydroxyvitamin D(3) in the serum. " 07/01/2014 - "Plasma 25 hydroxycholecalciferol (vitamin D) deficiency has been associated with adverse cardiovascular outcomes in epidemiologic studies. " 04/01/2012 - "We now report a novel CYP3A4-dependent pathway, the 4-hydroxylation of 25-hydroxyvitamin D(3) (25OHD(3)), the induction of which may contribute to drug-induced vitamin D deficiency. " 06/01/2011 - "Piglets are born with reduced plasma concentrations of 25-hydroxycholecalciferol (25-OH-D(3)) and are thus highly predisposed to vitamin D deficiency. " 11/01/2008 - "Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers."
5.	Neoplasms (Cancer) 09/01/2013 - "A systematic search of original, peer-reviewed studies on calcidiol at cancer diagnosis, and throughout treatment and survival, was conducted yielding 4,706 studies. " 01/01/2012 - "A bias in these studies might be that their basic assumption is linear dependence of cancer on serum calcidiol concentration. " 04/01/2015 - "The level of 25-hydroxyvitamin D3 can be considered as tumor burden index of NHL and can be used to evaluate the prognosis of NHL." 01/01/2012 - "The risk of pancreatic and oesophageal cancer seems to increase, when serum calcidiol concentration increases. " 01/01/2012 - "Optimal serum calcidiol concentration for cancer prevention."

Related Drugs and Biologics

1.	hydroxide ion
2.	Cholecalciferol (Vitamin D3)
3.	Calcium
4.	Calcitriol (Calcijex)
5.	Phosphorus
6.	Vitamin D
7.	Ergocalciferols (Ergocalciferol)
8.	Parathyroid Hormone (Parathormone)
9.	Alkaline Phosphatase
10.	Osteocalcin

Related Therapies and Procedures

1.	Buccal Administration
2.	Oral Administration
3.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Radiotherapy